What Happened

Bristol-Myers Squibb (BMS) cut 265 positions in New Jersey as part of a continuing corporate reorganization. The layoffs follow earlier site closures, including the Warren NJ facility, and reports that the entire Summit site has been listed for lease by JLL.

Who Is Affected

The 265 employees include site operations roles, not exclusively scientists. The cuts are part of a broader restructuring that has been ongoing since at least 2019, with multiple rounds of layoffs. Remaining staff in New Jersey sites (Princeton, Lawrenceville) face uncertainty as the company consolidates operations.

Market Impact

• BMS is facing major patent cliffs, with revenue expected to decline after current quarters. Cost-cutting measures are aimed at improving operating margins.
• The ongoing reorg creates opportunities for vendors in talent transition, outplacement, IT infrastructure migration, and change management.
• Competitors may poach displaced talent, especially in R&D and commercial roles.

What to Watch

Monitor further site closures in New Jersey, especially the Summit and Lawrenceville campuses. Watch for additional layoff rounds as BMS targets cost reductions through 2031. The company's shift of operations to Massachusetts (expensive research and commercial buildings) may signal further consolidation.

Related coverage

• Bristol Myers cuts another 265 jobs tied to New Jersey headquarters
• Novo Nordisk workforce reduction reaches 13,000 amid R&D restructuring
• TScan axes 75% of workforce, prioritizes solid tumor program
• ArsenalBio sheds most of staff in pivot to in vivo CAR-T